{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Clever S"],"funding":["COVID","Bayerischer Forschungsverbund FOR-COVID","Ministry of Science and Culture of Lower Saxony","Deutsche Forschungsgemeinschaft","DFG","Ministry of Science and Culture of Lower Saxony, Germany"],"pagination":["417"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10974247"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(3)"],"pubmed_abstract":["The sudden emergence of SARS-CoV-2 demonstrates the need for new vaccines that rapidly protect in the case of an emergency. In this study, we developed a recombinant MVA vaccine co-expressing SARS-CoV-2 prefusion-stabilized spike protein (ST) and SARS-CoV-2 nucleoprotein (N, MVA-SARS-2-ST/N) as an approach to further improve vaccine-induced immunogenicity and efficacy. Single MVA-SARS-2-ST/N vaccination in K18-hACE2 mice induced robust protection against lethal respiratory SARS-CoV-2 challenge infection 28 days later. The protective outcome of MVA-SARS-2-ST/N vaccination correlated with the activation of SARS-CoV-2-neutralizing antibodies (nABs) and substantial amounts of SARS-CoV-2-specific T cells especially in the lung of MVA-SARS-2-ST/N-vaccinated mice. Emergency vaccination with MVA-SARS-2-ST/N just 2 days before lethal SARS-CoV-2 challenge infection resulted in a delayed onset of clinical disease outcome in these mice and increased titers of nAB or SARS-CoV-2-specific T cells in the spleen and lung. These data highlight the potential of a multivalent COVID-19 vaccine co-expressing S- and N-protein, which further contributes to the development of rapidly protective vaccination strategies against emerging pathogens."],"journal":["Viruses"],"pubmed_title":["Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection."],"pmcid":["PMC10974247"],"funding_grant_id":["398066876/ GRK 2485/1","14 - 76103-184 CORONA-15/20","14—76103-184 CORONA-15/20 to A.V. and W.B.","398066876/GRK 2485/1 to A.V., G.S., and W.B.","F.2-F2412.32/1/45"],"pubmed_authors":["Volz A","Sutter G","Schunemann LM","Rosiak M","Baumgartner W","Clever S","Kumar S","Tscherne A","Beythien G","Limpinsel L","Freudenstein A","Tuchel T","Meyer Zu Natrup C","Kalodimou G","Hulskotter K","Gregor KM"],"additional_accession":[]},"is_claimable":false,"name":"Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection.","description":"The sudden emergence of SARS-CoV-2 demonstrates the need for new vaccines that rapidly protect in the case of an emergency. In this study, we developed a recombinant MVA vaccine co-expressing SARS-CoV-2 prefusion-stabilized spike protein (ST) and SARS-CoV-2 nucleoprotein (N, MVA-SARS-2-ST/N) as an approach to further improve vaccine-induced immunogenicity and efficacy. Single MVA-SARS-2-ST/N vaccination in K18-hACE2 mice induced robust protection against lethal respiratory SARS-CoV-2 challenge infection 28 days later. The protective outcome of MVA-SARS-2-ST/N vaccination correlated with the activation of SARS-CoV-2-neutralizing antibodies (nABs) and substantial amounts of SARS-CoV-2-specific T cells especially in the lung of MVA-SARS-2-ST/N-vaccinated mice. Emergency vaccination with MVA-SARS-2-ST/N just 2 days before lethal SARS-CoV-2 challenge infection resulted in a delayed onset of clinical disease outcome in these mice and increased titers of nAB or SARS-CoV-2-specific T cells in the spleen and lung. These data highlight the potential of a multivalent COVID-19 vaccine co-expressing S- and N-protein, which further contributes to the development of rapidly protective vaccination strategies against emerging pathogens.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-04-08T18:53:06.673Z","creation":"2025-04-04T19:11:22.553Z"},"accession":"S-EPMC10974247","cross_references":{"pubmed":["38543782"],"doi":["10.3390/v16030417"]}}